Key statistics
As of last trade Exelixis Inc (EX9:STU) traded at 37.11, -10.64% below its 52-week high of 41.53, set on May 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 37.01 |
|---|---|
| High | 37.81 |
| Low | 36.76 |
| Bid | 37.20 |
| Offer | 37.38 |
| Previous close | 37.50 |
| Average volume | 12.29 |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.45m |
| P/E (TTM) | 15.83 |
| Market cap | 11.44bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
